Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

All Drugs and Chemicals

Immunomodulating Agents

Mitogens

chemotherapy, EGFR TKI, immunotherapy, other

1L treatment

Chemotherapy, EGFR TKI, immunotherapy, other

2L Treatment

3L treatment

This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium

Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium

REtrospective, obserVational Study to Describe the Treatment Patterns and Outcomes of Epidermal Growth Factor Receptor Mutant (EGFRm) Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Patients in Belgium

observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Descriptive statitistics will be used to analyse these endpoints.

observation window: between date of diagnosis until the data cut-off, 1 september 2018, end of clinical activity or death, whichever comes first. Descriptive statistics will be used to analyse these endpoints.

observation window: between date of diagnosis until the data cut-off, 01 September 2018 until end of clinical activity or death, whichever comes first. Descriptive statistics will be used to analyse these endpoints.

observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Kaplan-Meier analysis will be used.

OS will be measured overall for all EGFRm NSCLC patients and depending on receipt of Osimertinib treatment and line of Osimertinib treatment.

observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first.

Kaplan-Meier analysis will be used.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium	NCT03761901	Carcinoma, Non-...	1L treatment 2L Treatment 3L treatment	18 Years -	AstraZeneca
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium	NCT03761901	Carcinoma, Non-...	1L treatment 2L Treatment 3L treatment	18 Years -	AstraZeneca
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium	NCT03761901	Carcinoma, Non-...	1L treatment 2L Treatment 3L treatment	18 Years -	AstraZeneca

Spots Global Cancer Trial Database for 2l treatment

Every month we try and update this database with for 2l treatment cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.